CD19 and primary central nervous system lymphoma: Thereafter, the same group tested a sequential approach of CD19/CD22 CAR-T cell cocktail infusion following ASCT in 13 patients with CNS lymphoma, achieving rather high rates of responses (ORR 82%, CR 55%), which appeared to be durable (median DOR 14.4 months) [86].